Drugs / GVAX pancreatic cancer vaccine
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02648282 | Jul 2016 → Jun 2022 | malignant pancreatic neoplasm | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | No outcome recorded |
| Phase 2 | NCT00727441 | Jul 2008 → May 2015 | malignant pancreatic neoplasm | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | No outcome recorded |
| Phase 2 | NCT00084383 | Jan 2002 → Dec 2005 | pancreatic ductal adenocarcinoma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GVAX pancreatic cancer vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00084383 ↗ |
| Action | Deplete | “build an immune response to kill tumor cells.” NCT00084383 ↗ |
| Modality | Vaccine | “Vaccine Therapy” NCT00084383 ↗ |
| Route | Other | “Given intradermally” NCT00727441 ↗ |